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Edited by Ned ManteiAbstract We previously showed that a trans-splicing ribozyme
reprograms tumor-related genes at the mRNA level, resulting in
the expression of therapeutic genes and that this approach can be
eﬃciently employed to target speciﬁc molecules. Here, we show
that trans-splicing ribozyme technology can be applied in molec-
ular imaging of speciﬁc RNA expression in living animals. We
exemplify this concept successfully by imaging mouse cytoskele-
ton-associated protein 2 (mCKAP2) expression in intrahepatic
tumor nodules using systemically delivered adenovirus harboring
mCKAP2-speciﬁc trans-splicing ribozyme.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Progress in cancer gene therapy is hampered by a lack of eﬃ-
cient molecular imaging technology for monitoring cancer-
related endogenous gene expression as a marker for tumor
location and progression in vivo [1]. Group I intron ribozymes
from Tetrahymena have been shown to trans-splice an attached
3 0 exon to a designated site on target RNA by replacing part of
the target RNA with another sequence [2,3]. To date, however,
attempts to apply group I ribozyme-mediated trans-splicing in
animals are hampered by limitations including; low target
speciﬁcity and activity in mammalian cells due to a short bind-
ing domain [4,5], and unavailability of an eﬃcient ribozyme
delivery system for appropriate targeting in vivo [6].
Recently, we reported on the successful development of an
adenovirus harboring human telomerase reverse transcriptaseAbbreviations: CKAP2, cytoskeleton-associated protein 2; TSM, trans-
spliced molecule; CMV promoter, cytomegalovirus immediate early
promoter; moi, multiplicity of infection; vp, virus particle
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doi:10.1016/j.febslet.2007.10.038(hTERT) RNA-speciﬁc trans-splicing ribozyme which was
stable and speciﬁc enough to be applied in vivo [7]. We also
demonstrated that the ribozyme can mark tumor cells express-
ing hTERT, and sensitize tumor cells to prodrug treatments in
mouse models [8].
Hasegawa et al. have shown that endogenous mRNAs can
be imaged by trans-splicing ribozyme in cultured cells [9].
However, this study did not establish the potential usefulness
of trans-splicing ribozyme for imaging mRNA in living animals.
We therefore examined whether the products of trans-splicing
can be imaged in deeper tissues of living animals such as liver.
We employed adenovirus harboring mouse cytoskeleton-asso-
ciated protein 2 (mCKAP2)-speciﬁc trans-splicing ribozyme as
a vehicle for in vivo imaging of mouse tumors. We found that
it is possible to visualize, in vivo, mCKAP2 RNA expression in
intrahepatic tumors of mice. This study thus conﬁrms the
potential of trans-splicing ribozyme as a molecular imaging
device.
2. Materials and methods
2.1. Generation of recombinant adenoviruses expressing trans-splicing
ribozyme
The mCKAP2-speciﬁc trans-splicing ribozyme was constructed as
previously described [10]. The resulting ribozyme ﬂanked by b-galacto-
sidase (lacZ) or luciferase (luc), was subcloned into a pAvCvSv shuttle
vector containing the cytomegalovirus immediate early (CMV)
promoter, and co-transfected into HEK293 cells with adenovirus back-
bone vector pJM17 [11]. We produced adenoviruses containing the
ribozyme with lacZ and luc as described before [8], designated as
Ad-mCR-lacZ and Ad-mCR-luc, respectively. As controls, we used
adenoviruses with lacZ (Ad-lacZ) or luc (Ad-luc) driven by the CMV
promoter and Ad-Mock, which has only the adenovirus backbone.
2.2. Cell culture
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (Gib-
coBRL, Carlsbad, CA) supplemented with 10% fetal bovine serum
(GibcoBRL) and 100 U/ml penicillin/streptomycin (GibcoBRL) at
37 C under 5% CO2.
2.3. Animal experiments
Six to 8 week-old male C57BL6 mice (Orient, Korea) were kept
under speciﬁc pathogen-free conditions at the Korean Food and Drug
Administration (KFDA) animal facility in accordance with AAALAC
International Animal Care policy (Accredited Unit-KFDA: Unit
Number-000996). The animals were acclimated to laboratory condi-
tions for at least 1 week before use.blished by Elsevier B.V. All rights reserved.
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Fig. 1. (A) X-gal staining of Hepa1-6 and HepG2 cells after
transfection by Ad-mCR-lacZ. Cells (2 · 105 cells/well) were transfec-
ted with Ad-mCR-lacZ at an moi of 0, 10, 30, or 50. X-gal stains were
observed at 100 magniﬁcation. (B) The speciﬁc activities of b-gal in
Hepa1-6 and HepG2 cells after Ad-mCR-lacZ transfection. Means of
measurements performed in triplicate are shown with bars indicating
S.E.
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inoculation of Hepa1-6 cells as previously reported with some modiﬁ-
cations [12]. Brieﬂy, a small longitudinal left upper ﬂank incision was
made to visualize the spleen, and 2 · 106 cells in 50 ll of PBS were
injected under the spleen capsule with a 29-gauge needle. After re-
moval of the needle, the spleen was returned to the abdominal cavity
and the abdominal wall was sutured with silk. Within 8–10 days, the
animals showed multiple intrahepatic tumor nodules, easily detectable
by gross inspection.
2.4. Detection of mCKAP2 and trans-spliced molecules by RT-PCR
The RT-PCR for mCKAP2 mRNA and production of trans-spliced
molecules (TSM) were performed as previously described [7] with
either mCKAP2 primers (5 0-GGGAGATCTATGGCAGAGTCC-
AGGAAACGCTTC-3 0 and 5 0-CACAGTCTGACCTGGCAAATCA
TCTCTTG-3 0) or TSM primers (5 0-AAAGGATCCAGGCGCGCT-
CATTAAGCGATGG-3 0 and 5 0-GGGCTCGAGCGGATTGACCG-
TAATGGA-30), respectively. To evaluate speciﬁcity of the
trans-splicing reaction of the ribozyme, the ampliﬁed product was
eluted, cloned into pBluescript (SK+/) and sequenced.
2.5. Analysis of b-galactosidase activity
To analyze b-galactosidase (b-gal) expression qualitatively and
quantitatively, we performed X-gal (5-bromo-4-chloro-3indoyl n-acet-
yl-b-D-galactosaminide) staining and b-gal activity assay, respectively,
as described before [8].
2.6. Analysis of luciferase activity
After lysing cells or tissues in lysis buﬀer (Promega), their luciferase
activity was assayed using Blight-Glo Luciferase Assay Sytem (Pro-
mega) according to manufacturer’s instructions. The reaction was
measured in counts per minute (cpm) in the luminometer and lumines-
cence results were reported as cpm per lg of protein.
2.7. Western blot analysis
Cells and tissues were lysed in PRO-PREP Protein Extraction Solu-
tion (Intron, Korea). After blotting, the membrane was incubated with
hybridoma culture supernatant with mouse monoclonal antibody
against mCKAP2 [13] or anti-b-actin antibody (Sigma, St. Louis,
MO) in blocking solution (5% non-fat milk in TBS containing 0.05%
Tween 20). Bound primary antibodies were then detected using horse-
radish peroxidase-conjugated anti-mouse antibody (Jackson Immuno-
Research, West Grove, PA).
2.8. In vivo bioluminescence imaging
A total of 1011vp of viruses in 50 ll Dulbecco’s PBS was injected via
tail veins of the mice. The virus was allowed to express the encoded
genes and distribute throughout the tumor for 1 day prior to imaging.
On the day of imaging, the mice were anesthetized with isoﬂuran-
mixed oxygen and injected with 200 ll of D-luciferin intraperitoneally
(150 mg/kg body weight) 10 min before imaging. The mice were then
scanned for 1 min using a Xenogen IVIS 200 cooled CCD camera
(Xenogen, Hopkinton, MA). The images shown are pseudoimages of
the emitted light in photon per second per cm2 per steridian (p/s/
cm2/sr), superimposed over the black and white photographic image
of the animal.
2.9. Statistical analysis
The data, expressed as means and standard errors (S.E.), was
analysed by the unpaired Student’s t-test. Statistical signiﬁcance was
set at P < 0.05.3. Results
3.1. Selective induction of reporter gene in mCKAP2- expressing
cells by trans-splicing ribozyme
After validating mCKAP2 as a feasible candidate target for
imaging tumor (Supplementary data and Fig. S1), we exam-
ined whether the adenovirus trans-splices eﬀectively. We trans-
fected mCKAP2+ Hepa1-6 cells with Ad-mCR-lacZ at 0, 10,
30, or 50 moi, and then stained them with X-gal. The humancell line HepG2 was used as a negative control, as trans-splic-
ing was not expected to occur with human CKAP2 mRNA.
Histological analysis conﬁrmed that Ad-mCR-lacZ selectively
induced transgene expression of b-gal in a virus dose-depen-
dent manner (Fig. 1A). However, we observed no b-gal expres-
sion in HepG2 cells although some non-speciﬁc blue staining
was noted at high viral doses.
We further analyzed b-gal expression levels by measuring
speciﬁc activities in cell lysates from the above experiment.
The b-gal activities (nmoles of ONPG hydrolyzed/min/mg pro-
tein) of Hepa1-6 and HepG2 cells transfected with Ad-mCR-
lacZ show that Ad-mCR-lacZ induced transgene expression
eﬃciently and selectively in a mCKAP2-dependent manner
(Fig. 1B).
3.2. trans-Splicing reaction by Ad-mCR-lacZ is speciﬁc for
mCKAP2 RNA and reduces target gene expression
To conﬁrm that the trans-splicing reaction was occurring at
the predicted site of mCKAP2 RNA, we analyzed mCKAP2+
Hepa1-6 and mCKAP2 HepG2 cells infected with Ad-mCR-
lacZ or Ad-lacZ by RT-PCR. When we transfected Ad-mCR-
lacZ, we detected TSMs only in Hepa1-6 cells but not in
HepG2 cells, while the primary transcripts (represented as lacZ
RNA production) were produced in both cell lines. In contrast,
TSMs were not generated by Ad-lacZ infected cells, regardless
of mCKAP2 expression (Fig. 2A). By sequence analysis of the
ampliﬁed fragment, we conﬁrmed that the trans-splicing ribo-
zyme correctly targeted the uridine at the predicted site of
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Fig. 2. (A) RT-PCR of trans-spliced product from Hepa1-6 cells
transfected with Ad-mCR-lacZ. The Hepa1-6 and HepG2 cells were
transfected with Ad-mCR-lacZ, Ad-lacZ, or Ad-Mock at 30 moi, and
cells treated with same volume of PBS (Mock) were used as a negative
control. The production of trans-splicing molecules (TSM) was shown
by RT-PCR, compared with ampliﬁcation of LacZ RNA. As an
internal control, mouse GAPDH (mGAPDH) RNA was ampliﬁed. (B)
Reduction of mCKPA2 expression by Ad-mCR-lacZ. The endogenous
mCKPA2 expression status in Hepa1-6 cells is shown by Western
blotting at 24 h after transfection with Ad-Mock, Ad-lacZ, and
Ad-mCR-lacZ at 30 moi. The upper and lower panels show the blots
probed by mCKAP2 and b-actin antibodies, respectively.
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Fig. 3. (A) Viral dose-dependent luciferase expression in Hepa1-6 cells
transfected with Ad-mCR-luc. Hepa1-6 cells were transfected with Ad-
mCR-luc at various moi’s. Means of measurements (cpm/lg of
protein) performed in triplicate are shown with bars indicating S.E.
(B) Background bioluminescence produced by systemically delivered
Ad-mCR-luc in non-tumor bearing mouse. Bioluminescence signals
were imaged in CCD camera and signal intensities were represented as
photon/second/cm2/steridian.
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Fig. S2).
We also examined whether the trans-splicing reaction medi-
ated by Ad-mCR-lacZ reduced the expression of mCKAP2.
One day after plating 1 · 106 Hepa1-6 cells in 100 mm dishes,
we transfected them with Ad-mCR-lacZ or Ad-lacZ at moi of
30. After 24 h, we looked for mCKAP2 protein expression in
protein extracts using b-actin expressions as an internal
control. We observed reduced expression of mCKAP2 in cells
transfected with Ad-mCR-lacZ, but not in those with Ad-lacZ
or Ad-Mock (Fig. 2B).
3.3. Systemic delivery of Ad-mCR-luc into non-tumor bearing
mouse results in low background bioluminescence signals
We ﬁrst evaluated whether Ad-mCR-luc expresses luciferase
in an mCKAP2-dependent manner. Hepa1-6 cells were plated
at 1 · 104 cells per well in a black 96-well plate and one day la-
ter, infected with Ad-mCR-luc at moi of 0, 1, 5, 10, 15, 30, or
50. Luciferase activity was determined after further incubation
for 48 h. We found viral dose-dependent increments in lucifer-
ase activities, suggesting that Ad-mCR-luc performs mCKAP2
targeting trans-splicing reaction (Fig. 3A).
To determine background bioluminescence produced by sys-
temically delivered Ad-mCR-luc in non-tumor bearing mice,
we injected 1 · 1011vp of Ad-mCR-luc via their tail veins and
performed in vivo molecular imaging. We detected little or
no bioluminescence signal in normal mice. In contrast,
Ad-luc which is under the control of the CMV promoter pro-
duced a high level of bioluminescence signal in liver (Fig. 3B).3.4. Detection of mCKAP2 expression in multiple intrahepatic
tumors in living mice
We established multiple intrahepatic tumors in C57BL/6
mice (n = 7) by intrasplenic inoculation of Hepa1-6 cells. After
8 days, we sacriﬁced two mice and conﬁrmed the appearance
of multiple intrahepatic tumor nodules by gross observations.
Then, we injected 1 · 1011vp Ad-mCR-luc (n = 4) and
Ad-Mock (n = 1) into the remaining mice via tail vein. After
24 h, we obtained bioluminescence images in vivo. Multiple
heterogeneous bioluminescence signals (maximum sig-
nal = 20000 p/s/cm2/sr) were detected in hepatic areas. After
external whole body imaging, direct imaging of multiple intra-
hepatic tumor nodules was performed in extracted livers. The
images obtained were consistent with corresponding whole
body images (Fig. 4A).
We also conﬁrmed reporter gene expression of Ad-mCR-luc
in normal liver tissues and tumor nodules by analyzing lucifer-
ase activities. We harvested four normal livers and seven liver
tumor nodules from mice used in the above imaging studies,
and measured luciferase activities. The observed cpm/lg of pro-
tein were 0.264 ± 0.252 for normal liver and 16.685 ± 10.690
for tumor nodules, reﬂecting a 100-fold higher luciferase
expression in tumor nodules than in normal livers (Fig. 4B).
In contrast, when we injected Ad-luc into tumor-bearing mice,
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Fig. 4. (A) Mice bearing multiple intrahepatic tumors were injected with Ad-mCR-luc via tail vein and imaged 24 h later. Direct images of tumor
nodules from extracted livers are also shown in the lower panel. A mouse injected with Ad-Mock was used as negative control. (B) Luciferase activity
of normal liver tissues and tumor nodules in Ad-mCR-luc injected mice (n = 6). Luciferase expression was measured and reported as cpm/lg of
protein in log scale. Means of measurements performed in triplicate are shown with bars indicating S.E. *P < 0.05, t-test.
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mal liver tissues (data not shown).4. Discussion
The microtubule stabilizing molecule CKAP2 is up-regu-
lated in highly proliferating cells and constitutes a useful target
both for therapeutic interventions and for speciﬁc imaging of
cancer [14]. We examined the feasibility of using the
mCKAP2-targeting trans-splicing ribozyme for imaging
endogenous mRNA in animals.
We showed that adenoviruses containing the ribozyme selec-
tively induce the reporter gene in an mCKAP2 expression-
dependent manner. When we infected mCKAP2+ Hepa1-6
with Ad-mCR-lacZ, we observed reporter gene expression
and the production of precise trans-spliced molecules, accom-
panied by a reduction of target gene expression. As expected,
there was no trans-splicing reaction in mCKAP2 HepG2
cells, because HepG2 cells are of human origin and express
human CKAP2 (hCKAP2) but not mCKAP2. These results
suggest that Ad-mCR-lacZ induces transgene expression eﬃ-
ciently and selectively in an mCKAP2-dependent manner.
When we replaced the reporter gene from lacZ (Ad-mCR-
lacZ) with luc (Ad-mCR-luc) for evaluating the feasibility of
Ad-mCR-luc as an imaging device, we found that systemic
delivery of Ad-mCR-luc into mice with intrahepatic tumors
produced bioluminescence signals suﬃcient for viewing exter-
nally in intact animals. The speciﬁcity of the bioluminescence
signal produced was conﬁrmed by direct imaging of extracted
livers and by comparing luciferase activities in tumor nodules
and normal liver. As a result, we observed higher expression
of luciferase in tumor nodules than in normal liver (P < 0.05,
Student’s t-test) while there was no statistical diﬀerence
between luciferase expression levels in normal liver vs. tumor
nodules after Ad-luc injection. Thus our results show that
luciferase encoded by Ad-mCR-luc is expressed only in tumors
and not in normal liver tissues. In contrast, Ad-luc, which is
constitutively expressed and is not regulated by ribozyme, is
expressed both in tumor and normal tissues. Therefore,trans-splicing ribozymes could be potentially useful tools for
imaging endogenous mRNA in living animals.
The potential usefulness of trans-splicing ribozymes for
imaging mRNA in animal systems is not clear from the study
of Hasegawa et al., which showed that trans-splicing ribozyme
can be used for imaging endogenous mRNA in cell cultures [9].
While Bhaumik and colleague did show splicing-dependent
bioluminescence imaging in living animals using spliceosome-
mediated RNA trans-splicing (SMaRT), they targeted an
exogenous gene which was driven by a strong constitutive
promoter, and not an endogenous mRNA [15]. Our method,
which visualizes endogenous mRNA in infused cancer cells,
potentially oﬀers an attractive and comprehensive approach
for imaging mRNA in vivo. Furthermore, there may be other
potential uses for this approach. For example, by replacing the
reporter gene with herpes simplex virus thymidine kinase gene,
one can expect to simultaneously image the tumor with isotope
labeled FIAU using a positron emission tomography, and
reduce tumor burden with ganciclovir treatment [16]. Thus,
established methods of non-invasive imaging could be used
to monitor the progress of gene therapy provided by tumor-
speciﬁc trans-splicing ribozyme.
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